ClinicalTrials.gg
DrugRead study by study

Lumateperone clinical trials

Also written ITI-007 and Caplyta.

studies test it
38
open now
15
in phase 3
21
first study started
2011
ClinicalTrials.gov finds 38 studies for lumateperone. How that becomes 38 here

Every study that search finds has been read, to see whether and how it gives lumateperone. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 38Found by its intervention search · See all 38 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 31 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 38Give lumateperone to participants
  3. 38Test it: the count on this site

Get an email when these change. Save the lumateperone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Dec 2019 · CAPLYTA · NDA 209500 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lumateperone
17
Lumateperone 42 mg
6
Lumateperone (ITI-007)
2

Brand

Caplyta
5

Development codes

ITI-007
8

Studies by the year they started

38 studies that test it; most in 2024 (10)

Studies that test lumateperone, by start year
YearStudies
20111
20143
20152
20162
20171
20191
20202
20215
20233
202410
20268

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
6
Phase 3
21
Phase 4
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 12

Intra-Cellular Therapies, Inc. (26) · University of Chicago (1) · Watim Medical & Dental College (1) · Future Options Research, LLC (1) · University of Texas at Austin (1) · Eric Lenze (1) · Jason Careri (1) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Risperidone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 4 in phase 3

Studies that test lumateperone, phase 3 first.

Studies

Open first, then newest update. How each study uses lumateperone has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 38

See all 38 studies that test lumateperone →

Behind its US label · 7 — the studies the FDA label of CAPLYTA describes

From the Clinical Studies section of CAPLYTA (2025-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 32 — no other medicine in its arm

Showing 20 of 32. See all 32 →

Tested with established drugs · 1 — they are given beside it
Tested in a combination · 5 — another drug in the study is under test too

Codes

What other systems call lumateperone · ClinicalTrials.gg INT001287

  • MeSH (NLM) C000705749lumateperoneConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 70BSQ12069LUMATEPERONEConfirmed FDA, NLM
  • RxNorm 2275602One source FDA
  • NCI Thesaurus C166975LumateperoneOne source FDA

Also registered as lumateperone tosylate (UNII JIE88N006O · RxNorm 2275731).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion